Edwards Lifesciences Q4 EPS Misses Estimates, Revenues Up on TAVR, Guides 8%-10% Growth
Edwards Lifesciences reported Q4 EPS below consensus estimates while revenue grew year-over-year to surpass expectations, driven by surging TAVR and TMTT procedures. Shares rose after management guided 8%-10% sales growth for full-year 2026.
1. Q4 Financial Results
Edwards Lifesciences posted Q4 EPS below the street consensus while delivering year-over-year revenue growth that exceeded forecasts. The overall revenue increase was propelled by higher procedure volumes across its core product portfolio.
2. Segment Performance
The transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapy (TMTT) segments saw significant adoption gains, driving the bulk of the revenue outperformance. Other product lines showed moderate growth but were overshadowed by the strong uptake in structural heart therapies.
3. Guidance and Market Reaction
Management issued guidance for 8%-10% sales growth in full-year 2026, reflecting confidence in sustained demand for its transcatheter platform. Shares climbed on the stronger outlook, as investors bet on continued expansion in core procedural markets.